Back to Search
Start Over
Mechanical thrombectomy is cost-effective versus medical management alone around Europe in patients with low ASPECTS.
- Source :
- Journal of NeuroInterventional Surgery; Jul2023, Vol. 15 Issue 7, p629-633, 5p
- Publication Year :
- 2023
-
Abstract
- Objective To demonstrate, by a cost-effectiveness analysis, the efficiency of mechanical thrombectomy (MT) versus medical management (MM) in patients with a low Alberta Stroke Program Early CT Score (ASPECTS) from the RESCUE Study. Methods A cost-effectiveness model was designed to project both direct medical costs and quality-adjusted life-years (QALYs) of MT versus MM in eight European countries (Spain, UK, France, Italy, Belgium, Germany, Sweden, and the Netherlands). Our model was created based on previously published health-economic data in those countries. Procedure costs, acute, mid-term, and long-term care costs were projected based on expected modified Rankin Scale (mRS) scores as reported in the RESCUE-Japan LIMIT trial. Results MT was found to be a cost-effective option in eight different countries across Europe (Spain, Italy, UK, France, Belgium, Germany, the Netherlands, and Sweden). with a lifetime incremental cost-effectiveness ratio varying from US$2 875 to US$11 202/QALY depending on the country. A cost-effectiveness acceptability curve showed 100% acceptability of MT at the willingness to pay (WTP) of US$40 000 for the eight countries. Conclusions MT is efficient versus MM alone for patients with low ASPECTS in eight countries across Europe. Patients with a large ischemic core could be treated with MT because it is both clinically beneficial and economically sustainable. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 17598478
- Volume :
- 15
- Issue :
- 7
- Database :
- Complementary Index
- Journal :
- Journal of NeuroInterventional Surgery
- Publication Type :
- Academic Journal
- Accession number :
- 166734792
- Full Text :
- https://doi.org/10.1136/jnis-2022-019849